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Abstract 
Background: Myocardial recovery with left ventricular assist device (LVAD) therapy is highly variable and difficult 
to predict. Next generation ribonucleic acid (RNA) sequencing is an innovative, rapid, and quantitative approach to 
gene expression profiling in small amounts of tissue. Our primary goal was to identify baseline transcriptional profiles 
in non-ischemic cardiomyopathies that predict myocardial recovery in response to LVAD therapy. We also sought to 
verify transcriptional differences between failing and non-failing human hearts.
Methods: RNA was isolated from failing (n = 16) and non-failing (n = 8) human hearts. RNA from each patient was 
reverse transcribed and quantitatively sequenced on the personal genome machine (PGM) sequencer (Ion torrent) 
for 95 heart failure candidate genes. Coverage analysis as well as mapping the reads and alignment was done using 
the Ion Torrent Browser Suite™. Differential expression analyses were conducted by empirical analysis of digital gene 
expression data in R (edgeR) to identify differential expressed genes between failing and non-failing groups, and 
between responder and non-responder groups respectively. Targeted cardiac gene messenger RNA (mRNA) expres-
sion was analyzed in proportion to the total number of reads. Gene expression profiles from the PGM sequencer were 
validated by performing RNA sequencing (RNAseq) with the Illumina Hiseq2500 sequencing system.
Results: The failing sample population was 75% male with an average age of 50 and a left ventricular ejection frac-
tion (LVEF) of 16%. Myosin light chain kinase (MYLK) and interleukin (IL)-6 genes expression were significantly higher 
in LVAD responders compared to non-responders. Thirty-six cardiac genes were expressed differentially between fail-
ing and non-failing hearts (23 decreased, 13 elevated). MYLK, Beta-1 adrenergic receptor (ADRB1) and myosin heavy 
chain (MYH)-6 expression were among those significantly decreased in failing hearts compared to non-failing hearts. 
Natriuretic peptide B (NPPB) and IL-6 were significantly elevated. Targeted gene expression profiles obtained from the 
Ion torrent PGM sequencer were consistent with those obtained from Illumina HiSeq2500 sequencing system.
Conclusions: Heart failure is associated with a network of transcriptional changes involving contractile proteins, 
metabolism, adrenergic receptors, protein phosphorylation, and signaling factors. Myocardial MYLK and IL-6 expres-
sion are positively correlated with ejection fraction (EF) response to LVAD placement. Targeted RNA sequencing of 
myocardial gene expression can be utilized to predict responders to LVAD therapy and to better characterize tran-
scriptional changes in human heart failure.
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Background
Left ventricular assist devices are commonly being uti-
lized to treat patients with advanced heart failure [1]. 
Mortality due to infection, bleeding, stroke, right heart 
failure and device malfunction continues as a significant 
problem in this population but increasingly patients are 
receiving these devices as destination therapy [1]. Car-
diac transplantation is not an option for the majority 
of these patients due to limitations in donor supply [2]. 
Myocardial recovery with LVAD therapy to the degree 
that allows device explant remains relatively rare for 
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with myocardial atrophy, changes in transcriptional pro-
files, and persistent abnormalities in protein phosphoryl-
ation [4, 5].
There is however increasing evidence that a subset of 
patients with LVAD therapy may remodel and recover 
sufficient myocyte function to allow device explant. Uti-
lizing ventricular unloading, myocardial conditioning 
and guideline directed heart failure medical therapy it 
may feasible to explant a significant number of patients 
with LVADs [6]. Myocardial recovery, while unusual 
in ischemic cardiomyopathies, may occur in 20–25% of 
non-ischemic cardiomyopathy patients [7].
Heart failure is characterized on a molecular level by 
transcriptional changes involving adrenergic signal-
ing mechanisms, calcium handling, contractile proteins, 
inflammation, and metabolism [8]. Next-generation 
sequencing allows for gene expression quantification, the 
study of epigenetic effects, identification of signal nucleo-
tide polymorphisms and measurement of transcriptional 
variations. Understanding the transcriptome is essential 
to understanding disease development, progression, and 
response to therapeutics. Transcriptional profiling is cur-
rently being used to guide treatment in many forms of 
cancer and to diagnose cardiac rejection. It is unknown 
if gene expression profiles can predict response to LVAD 
therapy. Our primary goal was to identify transcriptional 
profiles in non-ischemic cardiomyopathy patients that 
predict myocardial recovery. We also sought to verify 
transcriptional differences between failing and non-failing 
human hearts utilizing targeted non-optical sequencing.
Methods
This study was approved by the IRB at the University of 
Nebraska Medical Center. Failing tissue was obtained from 
non-ischemic cardiomyopathy patients (n = 16) who met 
standard criteria for LVAD placement either as destination 
therapy or as bridge to transplant. Tissue was obtained at 
the time of LVAD placement and stored in RNA later prior 
to freezing at −80 °C. Non-failing tissue was obtained by 
endomyocardial biopsy in transplant patients with normal 
cardiac function during routine surveillance (n = 8). Car-
diac function was evaluated by echocardiography.
Isolation of RNA
RNA was isolated from approximately 10–20 mg of car-
diac tissue using the RNeasy® Mini Kit (Qiagen®). Quan-
titative measurement of the RNA was taken using Qubit® 
RNA assay kit by Qubit 2.0 fluorometer (Invitrogen, Life 
Technologies).
Constructing RNA Library
Ion AmpliSeq™ RNA Library Kit and Custom Panels 
were utilized in the construction of RNA library for this 
investigation, and all experiments were carried out in 
accordance with the instructions from the manufacturer 
(Ion Torrent, Life Technologies). 10 ng of RNA, isolated 
from the cardiac tissue, is reverse transcribed to syn-
thesize complementary deoxyribonucleic acid (cDNA) 
using the Ion AmpliSeq™ RNA RT Module and Applied 
Biosystems thermal cycler. Next target sequences were 
amplified using Ion AmpliSeq™ RNA Custom Panels and 
Library Kit (life technologies). Our custom panel was 
designed to target 95 cardiac genes we previously have 
associated with reverse remodeling in heart failure uti-
lizing the Ion AmpliSeq™ Designer [8]. After amplifica-
tion of target sequences, primer sequences were partially 
digested using FuPa reagent from Ion AmpliSeq™ RNA 
Library Kit. Ion AmpliSeq™ adaptors were then ligated 
to the targeted deoxyribonucleic acid (DNA) and puri-
fication of those DNA fragments followed. Target DNA 
sequences were purified in a two-round purification pro-
cess with Dynabeads® Magnetic Beads where surplus 
primer sequences and high-molecular weight DNA are 
isolated and discarded from the solution. Following puri-
fication of the library, the library is amplified using Ion 
AmpliSeq™ RNA Library Kit and further purified using 
single-round purification with Dynabeads® Magnetic 
Beads. After amplification and purification of the library, 
Qubit® 2.0 fluorometer was used with Qubit® dsDNA HS 
Assay Kit to quantitatively measure the DNA library.
Preparation of targeted DNA template
Amplified stock library was diluted for appropriate Ion 
library preparation. Ion One Touch™ 2 System was uti-
lized to amplify individual diluted libraries via emulsion 
polymerase chain reaction (PCR) on ion sphere particles 
(ISPs). The template-positive ISPs were then enriched 
using Ion One Touch™ Enrichment System.
Sequencing
Sequencing was performed for all patients on the Ion 
Torrent PGM utilizing the Ion 316 chip. Coverage analy-
sis as well as mapping the reads and alignment was done 
using the Ion Torrent Browser Suite™. Gene expression 
profiles from the PGM sequencer were validated with a 
subsequent population by performing RNAseq with the 
Illumina Hiseq2500 sequencing system. RNAs from 7 
non failing and 3 failing samples were sequenced using 
the Illumina HiSeq2500 sequencing system (University of 
Nebraska Medical Center, DNA core facility). All paired 
end sequencing adaptors were trimmed using fqtrim 
and any reads shorter than 36 bases were discarded. A 
quality filter using fqtrim −q 5 was then applied to the 
reads. Paired end reads that passing those filters were 
mapped to Homo sapiens (release 37) reference sequence 
(GRCh37/hg19); using BowTie2 and TopHat2. The raw 
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read counts per gene were generated using the Rsubread 
package.
Statistical analysis
For the LVAD responder analysis the failing heart 
patients were divided into two groups: responders 
(∆LVEF ≥ 20%) and non-responders (∆LVEF < 20%). The 
expression of each gene on the cardiac panel was assessed 
in proportion to the total reads on the chip. The differ-
ential expression analysis was conducted using edgeR 
package in bioconductor developed by Robinson et al. [9, 
10]. Differential gene expression between the non-failing 
heart patients (n = 8) and failing heart patients (n = 16) 
was analyzed in a similar fashion. The gene Calreticulin 
3 (CALR3) was removed from the data due to 21 sam-
ples had zero counts for this gene. Spearman’s correlation 
coefficients were calculated to evaluate inter-platform 
consistency for raw counts and normalized counts per 
million (cpm) across two platforms (Ion Torrent and 
Illumina). The normalization factors for the data were 
estimated by the trimmed mean of the M-values normal-
ization method in the edgeR package and used to adjust 
for varying sequencing depths and potentially other tech-
nical effects across samples.
To further evaluate the biological pathways, log fold 
change utilizing Ingenuity Pathway Analysis (IPA) was 




We analyzed a total 34 of human heart samples, 16 fail-
ing, and 8 non-failing. Patient clinical characteristics are 
shown on Table 1. The failing sample population was 75% 
male with an average age 50. The failing patients had a 
New York Heart Association (NYHA) functional clas-
sification of III-IV and diabetes mellitus was common. 
EFs were measured before and after 3  months LVAD 
implantation. Change in ejection fraction (ΔEF) greater 
than 20 signifies responder after LVAD placement. By 
these criteria, 10 patients were non responders and 6 
patients were responders. The non- failing patients had 
EFs ranging from 60 to 65% whereas the EFs of LVAD 
patients were 15–25% at the time of implant. All patients 
in this study were recipients of the Heartmate II LVAD 
at the University of Nebraska Medical Center. Our center 
implanted 177 LVADs between June of 2006 and June of 
2016. Most of these implants (55%) were for critical car-
diogenic shock or a progressive declining clinical status 
despite inotropic support. The remainder were stable on 
inotropic therapy or with advanced resting symptoms. 
The overall clinical outcomes of LVAD therapy are shown 
in Fig. 1. Overall survival with LVAD as bridge to trans-
plant or destination therapy at one year is approximately 
80%. Very few patients historically have been explanted 
for recovery.
Responder vs non‑responder RNA‑Seq
Our study showed that MYLK (p  =  0.005) and IL 6 
(p < 0.0002) expression were significantly higher in LVAD 
responder patients than non-responder patients, Fig.  2. 
MYLK gene or myosin light chain kinase activates and 
regulates myosin light chain in the heart by phospho-
rylation. MYLK is necessary for normal cardiac function. 
Down regulation of MYLK expression increases the risk 
of heart failure [11–14]. Levels of IL-6 are found con-
siderably higher in myocardium and serum of patients 
receiving LVAD and with advanced heart failure [15–17]. 
Further analysis of an additional 5 patients pre and post 
LVAD who did not recover cardiac function and required 
transplant shows that LVAD therapy decreased myo-
cardial IL-6 (log fold change −2, p = 0.004) but did not 
change MYLK (p = 0.6).
Failing vs non‑failing RNA‑Seq results
Here we tried to understand the changes of cardiac genes 
expression during heart failure in association with con-
tractile dysfunction. We evaluated mRNA expression of 
95 cardiac gene using RNA-Sequence technology. It was 
found that 36 genes were differentially expressed when 
we compared failing versus non failing hearts (p < 0.05). 
Twenty-three genes were significantly decreased in failing 
Table 1 Patient characteristics
Variable Non‑failing hearts, n = 8 Failing hearts, n = 16
Age (years) 50 ± 13.30 50 ± 16.43
Male (%) 75% 75%
Caucasian/AA/hispanic-Asian (%) 12.5/75/12.5 70/20/10
Comorbid illness (%) DM 62.5% DM50%/HTN87.5%/Afb44%?CKD20%
LVEF at presentation (%) 60 ± 4.63 15.75 + 10.75
NYHA class N/A 3.68 + 0.60
Outcome (%) N/A LVAD in place 50%/heart transplant 44%/deceased 6%
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hearts including MYLK, ADRB1 and MYH6, Fig.  3. In 
contrast 13 genes were up-regulated including NPPB and 
IL-6, Fig. 4. A complete list of genes studied, p values and 
false discovery rates [18] are listed in Appendix.
Functional and pathway analysis in IPA
To further analyze the biological pathways, log fold 
change utilizing IPA was carried out on the targeted 
panel genes between failing and non-failing hearts. The 
differentially expressed genes involved in cardiomyopa-
thy and muscle formation were plotted. The top canonical 
pathways, molecular functions, upstream regulators and 
toxic effects are shown in Table 2. Figure 5 illustrates the 
network for genes that were differentially expressed, their 
molecular function and their relationship to different 
diseases including arrhythmia, hypertrophy of the heart, 
familial heart disease and necrosis of cardiac muscles. As 
shown in Fig.  5, eight genes of the targeted panel were 
involved in hypertrophy of the heart. Four genes clearly 
lead to activation of this pathway, up-regulation of IL-6 
(an activator) and down regulation of SMAD4, PRKCB 
and SLC25A4 (inhibitors). These molecular changes col-
lectively augment the hypertrophy signal of the heart. Six 
genes of the targeted panel were involved in the necrosis 
of cardiac muscle with a net z score of −2.115. Up-regu-
lation of HK2 and IL6 (known inhibitors) and down regu-
lation of ADRB1, PRKCB and TNF (known activators). 
The net effect of these changes are predicted to inhibit 
necrosis of the heart. Finally, nine molecules with a net of 
“not predicted effect” were involved in the familial cardi-
ovascular disease and arrhythmia that could be furthered 
studied.
Fig. 1 Competing outcomes for continuous flow LVADs (University of Nebraska, June 23 2006 to June 30 2016, n = 177)
Fig. 2 Gene expression levels associated with myocardial recovery. (ΔEF > 20 signifies responder to LVAD therapy. MYLK and IL6 expression was 
highly significant with p ≤ 0.005 and p ≤ 0.0002 respectively)
Page 5 of 9Dhar et al. J Transl Med  (2016) 14:327 
RNA‑Seq validation
To validate the results obtained from Ion torrent PGM 
sequencer by RNAseq analysis, Illumina HiSeq sequenc-
ing was utilized. Ten patients were sequenced for selected 
95 genes using RNAseq method on both sequencing plat-
forms (Illumina HiSeq and Ion Torrent). Illumina data 
were processed to obtain raw read counts for genes by 
BowTie, TopHat, and Rsubread packages respectively 
[19–21]. To evaluate inter-platform consistency for gene 
expression measures, we computed Spearman’s correlation 
between raw counts and normalized cpm from two plat-
forms for each individual, and the average spearman’s cor-
relation across 10 individuals. The results demonstrated 
high inter-platform consistency for gene expression meas-
ures across two platforms. (Spearman R ≥  0.83 for each 
patient sample, and average Spearman R = 0.84 using raw 
counts. Spearman R ≥  0.84 for each patient sample and 
average Spearman R = 0.86 using normalized cpm).
Discussion
The main findings of this study are that MYLK2 is dimin-
ished in heart failure, predicts response to LVAD therapy, 
and does not improve in advanced heart failure patients 
post LVAD who require transplantation. Our results fur-
ther characterize transcriptional changes between failing 
and non-failing human hearts and identify gene expres-
sion profiles associated with myocardial recovery on 
LVAD therapy. Heart failure is a heterogeneous disease 
process. Etiology, disease duration, cardiac remodeling, 
medical therapy, and molecular signatures have all been 
associated with myocardial recovery in non-ischemic 
cardiomyopathies. Recent studies suggest that up to 20 
percent of patients may recover their cardiac function 
within their first year post LVAD [22]. Molecular phe-
notyping is increasingly being utilized as a clinical tool 
to risk stratify patients and guide clinical decision mak-
ing. Transcriptional profiles are being utilized to screen 
heart transplant patient for rejection, identify patients 
with coronary disease, and guide treatment decisions for 
cancer patients. It may be feasible utilizing clinical char-
acteristics and molecular markers to risk stratify patients 
for early transplant versus more prolonged aggressive 
attempts to recover myocardial function with medical 
and device therapies. Previous studies have identified 
myocardial microRNA (miRNA) signatures as potential 
biomarkers of recovery. Our results suggest that mRNA 
patterns may also be helpful in risk stratifying patients 
undergoing LVAD therapy.
Baseline MYLK and IL-6 levels were both abnormal 
in failing myocardium and associated with response to 
LVAD therapy. Myosin is comprised of two heavy chain 
and two pairs of light chains. Myosin light chain 2 (MLC-
2) is a key regulatory component of myosin. Phospho-


























































































Fig. 4 Up regulated genes in failing myocardium (p < 0.05, log2-fold-
change of expression for failing vs. non-failing)
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sensitivity as well as sarcomere assembly [11, 23, 24]. 
MLC-2 can be phosphorylated by MYLK or protein kinase 
C and is dephosphorylated by light chain phosphatase. 
MLC-2 phosphorylation is known to be decreased in the 
end-stage failing human heart [25]. Our results would 
suggest that down-regulation of MYLK expression maybe 
contributing to this process. The association of higher 
levels of MYLK with improved myocardial recovery on 
LVAD therapy is consistent with prior evidence support-
ing this gene as an adaptive mechanism which facilities 
sarcomere organization in response to hypertrophic stim-
uli. Persistent abnormalities in MYLK post LVAD therapy 
in patients who did not recover are consistent with ongo-
ing stress and injury in this population.
IL-6 is known to be elevated systemically in heart fail-
ure and levels have been associated with severity of disease 
[26]. Elevated expression of myocardial IL-6 in advanced 
heart failure could be contributing to this process. IL-6 
can be produced by leukocytes, endothelial cells or vascu-
lar smooth muscle cells. Levels have been correlated with 
hemodynamic and neurohormonal variables. IL-6 is capa-
ble of producing myocardial dysfunction, vascular dilation, 
and muscle wasting. It is paradoxical that higher IL-6 lev-
els at baseline are associated with enhanced recovery with 
LVAD therapy. IL-6 appears to be an important mediator 
in ventricular hypertrophy and does increase nitric oxide 
production [27]. These mechanisms may play an important 
role in adapting to heart failure. IL-6 is extremely inducible 
in response to IL-1, TNFα, viral infection and angiotensin 
II peptide. It acts through two distinct mechanisms. The 
first one is a classic membrane receptor initiated pathway 
and the second one is trans-signaling pathway. It has been 
shown that IL-6 induces and activates signal transducer 
and activator of transcription 3 (STAT3) gene by engag-
ing the suppressor of cytokine signaling 3 (SOCS3) gene. 
Multiple studies showed that the activation of STAT3 pro-
motes cardiomyocyte survival and hypertrophy, as well 
as cardiac angiogenesis [28]. Our results suggest LVAD 
therapy decreases myocardial IL-6 expression substantially 
even in patients who do not recover. Hence, it is unlikely 
Table 2 IPA analysis
Name p value
Top canonical pathways
 Calcium signaling 9.78E−06
 Nitric oxide signaling in the cardiovascular 
system
2.07E−05
 Protein kinase A signaling 3.37E−05
 Tight junction signaling 1.53E−04







Molecular and cellular functions
 Cell morphology 1.49E−03 to 1.70E−08
 Cellular movement 1.40E−03 to 3.96E−08
 Gene expression 1.09E−03 to 3.96E−08
 Cell death and survival 1.57E−03 to 1.29E−07
 Cell-to-cell signaling and interaction 1.49E−03 to 2.21E−07
Top tox lists
 Cardiac hypertrophy 2.16E−08
 Cardiac necrosis/cell death 4.44E−06
 Increases heart failure 6.87E−06
 Cardiac fibrosis 1.45E−05
 Hepatic fibrosis 2.16E−05
Fig. 5 Ingenuity Pathway Analysis of log-fold change of genes in failing compared to non-failing
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to be contributing to the failure of myocardial recovery in 
patients post LVAD.
Heart failure is a complex molecular disease process 
involving more than IL-6 and MYLK. Numerous tran-
scriptional changes have been described involving a com-
plex gene network including contractile proteins, calcium 
handling, metabolism, signal transduction, apoptosis 
and inflammation [8, 29–31]. High throughput RNA 
sequencing now allows for the rapid quantification of 
gene expression in small amounts of tissue either globally 
or in a targeted fashion.
Most next generation sequencing technologies currently 
on the market use image capture, fluorescent detection 
or optical registration of some kind to capture sequenc-
ing data, which is then, converted to digital information. 
Our study utilized direct sequencing on a disposable semi-
conductor chip in a targeted fashion. This technology is 
relatively rapid, inexpensive and allows for quantification 
of mRNA over a broad range of gene expression levels. 
Between failing and non-failing human hearts we identify 
36 genes that are differentially expressed. Other studies 
have previously identified these genes in association with 
heart failure and sequencing by optical and non-optical 
methodologies produced similar results. This suggests that 
RNA sequencing might provide a valuable tool to further 
characterize the molecular mechanisms of heart failure.
This study has several limitations. In regards to recov-
ery, it is a single center retrospective analysis. There are 
several potential confounders that were not evaluated 
including genetic etiologies which could have impacted 
recovery independent of baseline gene expression. 
The study evaluated the transcriptome of only a lim-
ited number of genes. There are almost certainly other 
genes whose expression may be predictive of recovery 
or important mechanistically in heart failure. Finally, the 
transplant patients utilized as controls within this study 
may have different gene expression secondary to other 
factors such as immunosuppressive therapy independent 
of contractile dysfunction. For this reason we targeted 
candidate genes that previously have been identified in 
association with heart failure or myocardial remodeling.
While cardiac transplantation remains the gold stand-
ard for treating advanced heart failure, it is not an effec-
tive option for the majority of patients due to limitations 
in donor supply. The number of patients receiving left 
ventricular assist devices is growing exponentially. Less 
than 1% of patients are currently having their devices 
explanted for recovery. The rapid evolution in sequenc-
ing technologies may allow us to better classify LVAD 
patients who may recover. Prospective clinical trials to 
identify biomarkers of recovery are needed to help deci-
sion making in this population of patients. RNA signa-
tures and clinical characteristics may ultimately help 
identify a subset of patients who can recover cardiac 
function.
Conclusions
MYLK2 is diminished in heart failure, predicts response 
to LVAD therapy, and does not improve in advanced 
heart failure patients post LVAD who require transplan-
tation. Targeted next generation RNA sequencing allows 
rapid quantitative characterization of the transcriptional 
changes that occur in heart failure. Changes in this gene 
network involves contractile proteins, calcium handling, 
metabolism, signal transduction, apoptosis and inflam-
mation. Pathway analysis suggests that these changes 
ultimately contribute to cardiac hypertrophy, cardiac 
necrosis, cell death, increased heart failure risk and car-
diac fibrosis.
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Table 3 Failing vs non-failing
Gene id logFC p value FDR
PRKCB −1.819 2.11E−11 1.98E−09
RPS7 1.239 6.93E−09 3.26E−07
ACTA1 1.059 3.94E−07 1.23E−05
PABPC1L −1.873 1.22E−06 2.87E−05
ATRNL1 2.273 4.93E−06 9.27E−05
MYLK −2.307 1.08E−05 0.00017
NPPB 4.653 1.47E−05 0.00020
IL6 2.371 6.33E−05 0.00074
ZNF704 −0.585 0.00015 0.0015
TBX2 −1.120 0.00049 0.0044
PRPF38B −0.623 0.00051 0.0044
XPNPEP3 0.510 0.00176 0.014
SOAT1 −0.591 0.00210 0.015
VTN 0.919 0.00378 0.024
AGK 0.793 0.00425 0.024
HK2 0.928 0.00454 0.024
MSX2 0.806 0.00464 0.024
MYH6 −1.033 0.00471 0.024
ADRB1 −0.730 0.00486 0.024
TM2D1 −0.394 0.00570 0.027
PLEKHA3 −0.513 0.00611 0.027
CASQ1 0.743 0.00649 0.028
SMAD4 −0.347 0.00943 0.038
GLS −0.515 0.00978 0.038
JUP −0.437 0.010 0.038
SPINT2 −0.639 0.012 0.044
SMNDC1 −0.347 0.015 0.053
COQ10B 0.410 0.017 0.057
PLN −0.461 0.018 0.059
TNNI3 0.613 0.021 0.067
PDIA6 −0.392 0.022 0.068
CENPQ −0.429 0.024 0.070
TMEM139 −0.642 0.036 0.103
SLC25A4 −0.315 0.041 0.112
RYR2 −0.449 0.042 0.112
TNF −0.814 0.048 0.125
C10orf88 −0.325 0.051 0.129
MYL2 0.544 0.055 0.135
MYOZ2 0.424 0.067 0.161
DSP −0.369 0.068 0.161
SLC9B2 −0.391 0.075 0.170
ROBO4 −0.354 0.076 0.170
PPIC 0.351 0.081 0.177
DES 0.446 0.083 0.177
CETP −0.727 0.101 0.212
TNNC1 0.355 0.117 0.234
NUFIP2 0.272 0.117 0.234
BAG3 0.308 0.120 0.235
TBL1XR1 0.227 0.136 0.261
Table 3 continued
Gene id logFC p value FDR
STARD3 −0.275 0.152 0.286
ACTN2 0.289 0.172 0.318
DGAT1 −0.233 0.177 0.321
LAMP2 −0.240 0.183 0.323
SPCS3 −0.186 0.186 0.323
CAPZA2 −0.266 0.191 0.327
ERF −0.233 0.209 0.351
UBE2B −0.254 0.228 0.377
LDB3 −0.233 0.236 0.382
ACTC1 0.284 0.240 0.382
VCL 0.267 0.246 0.385
DSG2 −0.206 0.255 0.393
TAZ −0.219 0.276 0.418
IL1B −0.557 0.305 0.455
RPS18 0.198 0.311 0.457
ARHGEF15 −0.199 0.322 0.459
TMEM43 0.229 0.323 0.459
SGCD −0.195 0.329 0.462
ATP6V1B2 0.145 0.343 0.474
PCDHB15 −0.220 0.361 0.492
MYBPC3 −0.156 0.377 0.506
RFXAP −0.179 0.423 0.560
DSC2 −0.116 0.447 0.583
TPM1 0.171 0.464 0.597
WDR44 0.111 0.500 0.636
DMD 0.150 0.531 0.666
ME2 −0.100 0.564 0.697
RAP2B −0.132 0.598 0.729
PKP2 0.126 0.612 0.737
ERCC4 0.078 0.648 0.771
PRKAG2 0.087 0.661 0.771
PHF2 −0.069 0.665 0.771
MAGEE1 −0.066 0.726 0.832
HIF1AN −0.044 0.737 0.835
CAV3 0.052 0.761 0.851
ABCC9 −0.049 0.793 0.877
TNNT2 −0.044 0.821 0.898
MYH7 −0.021 0.920 0.983
LEMD3 −0.012 0.922 0.983
COX8A 0.018 0.935 0.983
IRF2 −0.008 0.949 0.983
MYL3 −0.007 0.958 0.983
FPGT −0.002 0.977 0.983
BCL2L13 −0.002 0.980 0.983
PPM1D 0.008 0.983 0.983
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